KLHDC7B as a novel diagnostic biomarker in urine exosomal mRNA promotes bladder urothelial carcinoma cell proliferation and migration, inhibits apoptosis
Jiayin Hou
Institute of Medical Technology, Peking University Health Science Center, Beijing, China
Department of Clinical Laboratory, Peking University First Hospital, Beijing, China
Search for more papers by this authorHaiming Huang
Department of Clinical Laboratory, Peking University First Hospital, Beijing, China
Search for more papers by this authorJunyi Xie
Department of Urology, Peking University First Hospital and Institute of Urology, Beijing, China
Search for more papers by this authorCorresponding Author
Wei Yu
Department of Urology, Peking University First Hospital and Institute of Urology, Beijing, China
Correspondence Haixia Li, Department of Clincal Laboratory, Peking University First Hospital, Beijing, China.
Email: [email protected]
Wei Yu and Han Hao, Department of Urology, Peking University First Hospital and Institute of Urology, Beijing, China.
Email: [email protected] and [email protected]
Search for more papers by this authorCorresponding Author
Han Hao
Department of Urology, Peking University First Hospital and Institute of Urology, Beijing, China
Correspondence Haixia Li, Department of Clincal Laboratory, Peking University First Hospital, Beijing, China.
Email: [email protected]
Wei Yu and Han Hao, Department of Urology, Peking University First Hospital and Institute of Urology, Beijing, China.
Email: [email protected] and [email protected]
Search for more papers by this authorCorresponding Author
Haixia Li
Institute of Medical Technology, Peking University Health Science Center, Beijing, China
Department of Clinical Laboratory, Peking University First Hospital, Beijing, China
Correspondence Haixia Li, Department of Clincal Laboratory, Peking University First Hospital, Beijing, China.
Email: [email protected]
Wei Yu and Han Hao, Department of Urology, Peking University First Hospital and Institute of Urology, Beijing, China.
Email: [email protected] and [email protected]
Search for more papers by this authorJiayin Hou
Institute of Medical Technology, Peking University Health Science Center, Beijing, China
Department of Clinical Laboratory, Peking University First Hospital, Beijing, China
Search for more papers by this authorHaiming Huang
Department of Clinical Laboratory, Peking University First Hospital, Beijing, China
Search for more papers by this authorJunyi Xie
Department of Urology, Peking University First Hospital and Institute of Urology, Beijing, China
Search for more papers by this authorCorresponding Author
Wei Yu
Department of Urology, Peking University First Hospital and Institute of Urology, Beijing, China
Correspondence Haixia Li, Department of Clincal Laboratory, Peking University First Hospital, Beijing, China.
Email: [email protected]
Wei Yu and Han Hao, Department of Urology, Peking University First Hospital and Institute of Urology, Beijing, China.
Email: [email protected] and [email protected]
Search for more papers by this authorCorresponding Author
Han Hao
Department of Urology, Peking University First Hospital and Institute of Urology, Beijing, China
Correspondence Haixia Li, Department of Clincal Laboratory, Peking University First Hospital, Beijing, China.
Email: [email protected]
Wei Yu and Han Hao, Department of Urology, Peking University First Hospital and Institute of Urology, Beijing, China.
Email: [email protected] and [email protected]
Search for more papers by this authorCorresponding Author
Haixia Li
Institute of Medical Technology, Peking University Health Science Center, Beijing, China
Department of Clinical Laboratory, Peking University First Hospital, Beijing, China
Correspondence Haixia Li, Department of Clincal Laboratory, Peking University First Hospital, Beijing, China.
Email: [email protected]
Wei Yu and Han Hao, Department of Urology, Peking University First Hospital and Institute of Urology, Beijing, China.
Email: [email protected] and [email protected]
Search for more papers by this authorAbstract
Bladder cancer is a common kind of urinary system cancer, in which bladder urothelial carcinoma (BLCA) comprises approximately 90% of all bladder cancer types. In our previous study, we discovered KLHDC7B in urine exosomal messenger RNA (mRNA) as a prospective molecular marker for bladder cancer detection. To systematically study the role and mechanism of KLHDC7B in BLCA, we focused on the most common type of BLCA in this study. First, we used RNA sequencing to discover that KLHDC7B was considerably increased in BLCA patients' urine exosomes compared to healthy controls. Then, we validated this result in an independent cohort and identified it as an effective tool for diagnosing and distinguishing high-grade and low-grade BLCA. Finally, we studied the role and mechanism of KLHDC7B in BLCA at the cellular level, providing a functional basis for its expression as a novel laboratory diagnostic biomarker for BLCA exosomal mRNA, which has important theoretical and clinical significance.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Supporting Information
| Filename | Description |
|---|---|
| mc23652-sup-0001-Supplementary_Material.docx43.1 KB | Supporting information. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Berdik C. Unlocking bladder cancer. Nature. 2017; 551(7679): S34-S35.
- 2Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021; 79(1): 82-104.
- 3Eble JN, Sauter G, Epstein J, Sesterhenn I, eds. Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumors. Vol. 7, 3rd ed.; 2004.
- 4Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016; 70(1): 106-119.
- 5Schmitz-Dräger BJ, Droller M, Lokeshwar VB, et al. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int. 2015; 94(1): 1-24.
- 6Lotan Y, O'Sullivan P, Raman JD, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol. 2017; 35(8): 531.e15-531.e22.
- 7Huang H, Du J, Jin B, et al. Combination of urine exosomal mRNAs and lncRNAs as novel diagnostic biomarkers for bladder cancer. Front Oncol. 2021; 11:667212.
- 8Martín-Pardillos A, Cajal SRY. Characterization of Kelch domain-containing protein 7B in breast tumours and breast cancer cell lines. Oncol Lett. 2019; 18(3): 2853-2860.
- 9Jeong G, Bae H, Jeong D, et al. A Kelch domain-containing KLHDC7B and a long non-coding RNA ST8SIA6-AS1 act oppositely on breast cancer cell proliferation via the interferon signaling pathway. Sci Rep. 2018; 8:12922.
- 10Li G, Sun L, Mu Z, Huang Y, Fu C, Hu B. Ectopic WWOX expression inhibits growth of 5637 bladder cancer cell in vitro and in vivo. Cell Biochem Biophys. 2015; 73(2): 417-425.
- 11Płuciennik E, Nowakowska M, Stępien A, et al. Alternating expression levels of WWOX tumor suppressor and cancer-related genes in patients with bladder cancer. Oncol Lett. 2014; 8(5): 2291-2297.
- 12Kołat D, Kałuzińska Ż, Bednarek AK, Płuciennik E. Fragile gene WWOX guides TFAP2A/TFAP2C-dependent actions against tumor progression in grade II bladder cancer. Front Oncol. 2021; 11:621060.
- 13Taouis K, Driouch K, Lidereau R, Lallemand F. Molecular functions of WWOX potentially involved in cancer development. Cells. 2021; 10(5): 1051.
- 14Ramos D, Abba M, López-Guerrero JA, et al. Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours. Histopathology. 2008; 52(7): 831-839.
- 15Bonin F, Taouis K, Azorin P, et al. VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX. BMC Biol. 2018; 16(1): 109.
- 16Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020; 367(6478): 640-664.
- 17Zhan Y, Du L, Wang L, et al. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer. Mol Cancer. 2018; 17: 142.
- 18Bian B, Li L, Ke X, et al. Urinary exosomal long non-coding RNAs as noninvasive biomarkers for diagnosis of bladder cancer by RNA sequencing. Front Oncol. 2022; 12:976329.
- 19Ding J, Ji X, Liu L, et al. A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival. J Cancer Res Clin Oncol. 2023; 149: 7857-7876.
- 20Street JM, Koritzinsky EH, Glispie DM, Yuen PST. Urine exosome isolation and characterization. Methods Mol Biol. 2017; 1641: 413-423.
- 21EL Andaloussi S, Mäger I, Breakefield XO, Wood MJA. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5): 347-357.
- 22Chou PY, Lin SR, Lee MH, Schultz L, Sze CI, Chang NS. A p53/TIAF1/WWOX triad exerts cancer suppression but may cause brain protein aggregation due to p53/WWOX functional antagonism. Cell Commun Signal. 2019; 17: 76.
- 23Leber B, Lin J, Andrews DW. Still embedded together binding to membranes regulates Bcl-2 protein interactions. Oncogene. 2010; 29(38): 5221-5230.
- 24Mignard V, Lalier L, Paris F, Vallette FM. Bioactive lipids and the control of bax pro-apoptotic activity. Cell Death Dis. 2014; 5(5):e1266.
- 25Zhang JJ, Cai LJ, Pang K, et al. Paeonol inhibits proliferation and induces cell apoptosis of human T24 and 5637 bladder cancer cells in vitro and in vivo. Clin Transl Oncol. 2021; 23(3): 601-611.
- 26Luo G, Wang M, Wu X, et al. Long non-coding RNA MEG3 inhibits cell proliferation and induces apoptosis in prostate cancer. Cell Physiol Biochem. 2015; 37(6): 2209-2220.
- 27Zhu L, Wang Y, Lv W, et al. Schizandrin A can inhibit non‑small cell lung cancer cell proliferation by inducing cell cycle arrest, apoptosis and autophagy. Int J Mol Med. 2021; 48(6): 214.
- 28Huang W, Wang Y, Zhu H, Wu Y, Xie X, Wang D. [Solasonine-induced apoptosis in lung cancer cell line H446 and its mechanism]. Zhongguo Fei Ai Za Zhi. 2015; 18(7): 416-421.
